With Increasing New Drug INDs Projected, How Much More Workload Can US FDA Handle?

Meanwhile, the biosimilars program is expecting essentially flat application numbers, but more manufacturing supplements and more development meetings, which likely is an indication of the sector’s flourishing in the US.